Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).”In the company’s words, NCT03249103 on ClinicalTrials.gov
- Tested for
- Fibromyalgia (2 trials), Diabetic Peripheral Neuropathic Pain
- Main trialPhase 2
- “The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy (H-MRS) in fibromyalgia subjects on active drug versus placebo.”In the company’s words, NCT03249103 on ClinicalTrials.gov
Other drugs for Fibromyalgia
- AXS-14Axsome Therapeutics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 18 Apr 2019 | Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia | |
| Phase 2Completed | 23 Feb 2022 | Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) | |
| Phase 2Completed | 16 Jun 2022 | Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026